Drug Trial Radar · NCT04877691
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
367
Actual
Start
Jun 8, 2021
Primary completion
Aug 22, 2025
Study completion Nov 6, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- May 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
Conditions
- Systemic Lupus Erythematosus
Interventions
Medi-546Drug
Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
PlaceboDrug
Solution for injection in aPFS
Primary outcomes
What the sponsor says the trial is designed to measure.
- British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responseTime frame: At week 52
Locations
140 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Paradise Valley, Arizona
Research Site
Phoenix, Arizona
Research Site
El Cajon, California
Research Site
Fullerton, California
Research Site
Hemet, California
Research Site
La Mesa, California
Research Site
Los Angeles, California
Research Site
Menifee, California
Research Site
Upland, California
Research Site
Aurora, Colorado
Research Site
Brandon, Florida
Research Site
Clearwater, Florida
Research Site
Clearwater, Florida
Research Site
Miami, Florida
Research Site
Tampa, Florida
Research Site
Tampa, Florida
Research Site
Idaho Falls, Idaho
Research Site
Flint, Michigan
Research Site
Lansing, Michigan
Research Site
Newark, New Jersey
Research Site
Las Cruces, New Mexico
Research Site
Brooklyn, New York
Research Site
Manhasset, New York
Research Site
New York, New York
Research Site
Potsdam, New York
Research Site
Charlotte, North Carolina
Research Site
Charlotte, North Carolina
Research Site
Oklahoma City, Oklahoma
Research Site
Pittsburgh, Pennsylvania
Research Site
Reading, Pennsylvania
Research Site
Memphis, Tennessee
Research Site
Grapevine, Texas
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Mendoza, Argentina
Research Site
Pergamino, Argentina
Research Site
Quilmes, Argentina
Research Site
Rosario, Argentina
Research Site
Salta, Argentina
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.